contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


elicera-therapeutics-will-participate-in-upcoming-industry-and-investor-conferences-during-the-fall

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

Elicera Therapeutics AB is a clinical phase cell and gene therapy company that develops the next generation of immuno-oncology treatments. The work is based on high-profile long-standing research conducted by Professor Magnus Essand's research group at Uppsala University and has resulted in the development of four drug candidates, including two CAR T cells and two oncolytic viruses.

Elicera Therapeutics

Gothenburg, September 3, 2024 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on CAR T-cell therapies and ...

<div class="abstract">Gothenburg, September 3, 2024 - Elicera Therapeutics AB (publ), a clinical stage cell&nbsp;and gene therapy company developing next generation cancer treatments based on CAR T-cell therapies and oncolytic viruses, armed with its proprietary and commercially available technology platform iTANK, announces that the company will participate in the following industry and investor conferences during the fall of 2024:</div>ISCT Europe 2024 Regional Meeting, September 4&nbsp; Elicera Therapeutics will participate in the annual conference organized by the scientific network International Society for Gene &amp; Cell Therapy. For more information:&nbsp;<a href="https://www.isctglobal.org/iscteu2024/home">https://www.isctglobal.org/iscteu2024/home</a>CICON24 (Eighth International Cancer Immunotherapy Conference), September 8&nbsp; Elicera Therapeutics' co-founder and CSO, Magnus Essand, has been invited to present iTANK and the company's development of CAR T-cell therapies. For more information:&nbsp;www.cancerimmunotherapyconference.orgBiostock Investor Meeting, September 12&nbsp; Elicera Therapeutics' CEO, Jamal El-Mosleh, will present the company at an investor meeting organized by Biostock. For more information:&nbsp;<a href="https://www.biostock.se/investing-in-life-science/">https://www.biostock.se/investing-in-life-science/</a>NLSDays 2024, September 18-19&nbsp; Elicera Therapeutics will participate in Nordic Life Science Days, the Nordic region's largest business conference in life science. For more information:&nbsp;www.nlsdays.com/about-the-eventMiltenyi Cell and Gene Therapy Summit 2024, October 8&nbsp; Elicera Therapeutics' co-founder and CSO, Magnus Essand, has been invited to present iTANK and the company's development of CAR T-cell therapies. For more information:&nbsp;www.miltenyibiotec.com/UN-en/about-us/conferences-and-events/miltenyi-biotec-s-cell-and-gene-therapy-days.htmlBIO-EUROPE, November 4&nbsp; Elicera Therapeutics will participate in Europe's largest business conference in life science. For more information:&nbsp;www.informaconnect.com/bioeuropeBiostock Summit, November 19&nbsp; Elicera Therapeutics will present at the annual investor meeting organized by Biostock. The company's presentation will be published on their website.

Elicera Therapeutics will participate in upcoming industry and investor conferences during the fall

Return on capital (ROE, ROI, ROIC, RONIC)

What does negative working capital mean and why is it a good thing?

Drug development investment: Value creation through M&As and licensing agreements

Income statement

Amazon continues to grow in Sweden

Stay up to date with our newsletter